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Abstract
Background: Cholesterol-lowering medications such as statins have anti-inflammatory and antioxidant properties,
which may be beneficial for treating depression and improving mood. However, evidence regarding their effects
remains inconsistent, with some studies reporting links to mood disturbances. We aimed to conduct a meta-
analysis to determine the impact of statins on psychological wellbeing of individuals with or without
hypercholesterolemia.
Methods: Articles were identified using medical, health, psychiatric and social science databases, evaluated for
quality, and data were synthesized and analyzed in RevMan-5 software using a random effects model.
Results: The 7 randomized controlled trials included in the analysis represented 2,105 participants. A test for
overall effect demonstrated no statistically significant differences in psychological wellbeing between participants
receiving statins or a placebo (standardized mean difference (SMD) = -0.08, 95% CI -0.29 to 0.12; P = 0.42).
Sensitivity analyses were conducted to separately analyze depression (n = 5) and mood (n = 2) outcomes; statins
were associated with statistically significant improvements in mood scores (SMD = -0.43, 95% CI -0.61 to -0.24).
Conclusions: Our findings refute evidence of negative effects of statins on psychological outcomes, providing
some support for mood-related benefits. Future studies could examine the effects of statins in depressed
populations.
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Background
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors) are considered first-line agents for treating
hypercholesterolemia in the primary and secondary pre-
vention of cardiovascular disease (CVD). Statins lower
cholesterol by inhibiting a key enzyme that plays a central
role in cholesterol production in the liver, in turn suppres-
sing the inflammatory response to endotoxin and blunting
lipopolysaccharide-induced monocyte tissue factor expres-
sion [1]. Indeed, the benefits of statin use for individuals
with existing coronary disease are well established; a num-
ber of past studies have demonstrated their efficacy. The
Long-term Intervention with Pravastatin in Ischaemic
Disease (LIPID) [2], Scandinavian [3] and Sacks et al. [4]
studies have all demonstrated positive treatment effects of
statins on CVD-related outcomes. However, despite their
widespread use, conjecture remains regarding the risk-
benefit profile of statins for the primary prevention of
CVD, with emerging evidence of adverse effects of rapid
lipid lowering on a range of psychological outcomes.
Data from prospective, case-control and longitudinal
studies have identified low mood, aggression [5] and sui-
cide [6] as possible side effects of cholesterol-lowering
treatment. While the underlying physiology is not fully
understood, authors of a review that found an association
between low serum cholesterol and suicide suggest that
lower serum cholesterol may be associated with reduced
serotonin in the brain [7]. Reductions in serotonin have
been associated with an inability to suppress aggressive
behavior, thus leading to poorer mental health outcomes.
Such research has resulted in cholesterol-lowering
agents, such as statins, being inextricably linked with* Correspondence: AONEIL@BarwonHealth.org.au
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adverse psychological outcomes. However, more recent
data have challenged this notion.
Statin treatment has now been shown to be associated
with improved psychological well-being in individuals
with underlying coronary disease, independent of serum
cholesterol levels. Young-Xu et al. compared 140 patients
who had continuous use of statins, with 231 who did not.
Statins were associated with a reduced risk of depression
(OR 0.63, 95% CI 0.43 to 0.93) and anxiety (OR 0.69, 95%
CI 0.47 to 0.99), after controlling for potential confoun-
ders [8]. Data from several other studies conducted in
hypercholesterolemic [9], cardiac [10,11] and healthy [12]
populations have provided further support for this asso-
ciation. A fourfold reduction in risk for depression
among individuals taking statins has been observed
[10,11]. Using observational data, Pasco et al. found that
age-adjusted odds ratio for major depressive disorder
(MDD) for statin users was 0.13 (95% CI 0.02 to 1.02)
[12]. This effect has been demonstrated in both the short
term (9-month follow-up) [10] and long term (6-year
follow-up) [11].
Using the existing evidence, a review has recently been
conducted in an attempt to confirm a directional rela-
tionship between statin use and psychological outcomes.
While and Keen [13] found conflicting evidence for a
relationship between mood and statins, based on the
findings of eight studies (prospective, observational, ran-
domized controlled trials (RCTs)). A limitation of this
review was that the authors did not meta-analyze the
data in order to calculate effect sizes, therefore were
unable to define the effects of statins on psychological
outcomes. Other recent reviews conducted in the area
of statin research that have performed a meta-analysis
have failed to shed any light on the effects of statins on
psychological outcomes; none have included mental
health outcomes [5,14,15]. Thus, the true effect of sta-
tins on psychological wellbeing remained largely
undetermined.
Using predetermined criteria, our aim was to conduct
the first meta-analysis to confirm the impact of statins
on psychological wellbeing, in individuals with and with-
out hypercholesterolemia.
Methods
The literature search identified articles that measured the
effects of statins on psychological outcomes (depression,
anxiety, mood, psychological distress) in those with and
without hypercholesterolemia. The following databases
were utilized: Cochrane Central Register of Controlled
Trials, PubMed, OVID, Medline, Proquest, CINAHL
plus, SCOPUS, Web of Knowledge. Reference lists of
relevant reviews and individual studies in this area were
manually examined. Search engines (Google Scholar)
were used to explore grey literature. No limits on year of
publication were set. Studies were limited to those pub-
lished in English. Bibliographies of extracted references
were manually searched for relevant references.
Selection criteria
Articles included in the review were RCTs meeting the
following inclusion criteria: (1) ≥1 placebo/control condi-
tion; (2) random assignment to treatment condition of a
statin agent (simvastatin, atorvastatin, fluvastatin, lovasta-
tin, mevastatin, pitavastatin, pravastatin, rosuvastatin,
cerivastatin) alone/in conjunction with a dietary program;
(3) documentation of psychological outcomes (depres-
sion, distress, mood) as a primary/secondary endpoint;
(4) minimum 2 weeks of treatment (period over which
change in mood/depressed state is monitored); and (5) a
defined study sample detailing medical status (risk of
CVD/hypercholesterolemia, hypercholesterolemia, his-
tory of CVD, healthy). Two independent searches that
applied this strategy were conducted by the leading
authors (AO’N and LS). Results of the searches were
then compared and inter-rater reliability assessed. Where
consensus for the inclusion of a study was not reached,
the third author was consulted.
Data extraction and validity assessment
To avoid coder bias, data from included articles were
extracted by a single investigator and collated into a table
for review by the author group. The extraction table
included study author, title, journal, drug type and dosage,
population, design, assessment points, psychological mea-
sure and key findings. Trial quality was assessed according
to an inventory guided by Cochrane Collaboration recom-
mendations on evaluating validity. These criteria included:
randomization; allocation concealment; blinding; comple-
teness of follow-up; and intention-to-treat analysis. Due to
the different measures used to assess depression and
mood across studies, estimates were calculated using stan-
dardized mean differences (SMD). A random effects
model was employed to account for differences in trial
designs (for example, crossover, parallel) [16]. Where stan-
dard deviations were not reported in the publication (CIs
or standard error were instead presented), standard equa-
tions for conversion were used to calculate SMD [17].
Where medians and interquartile ranges (IQRs) were
reported, medians were substituted for means as recom-
mended by Hozo et al., who suggest that when sample
size exceeds 25, the median is the best estimator [18].
IQRs were transformed using methods derived from Hozo
et al. Where a study [19] presented only a between-group
change score, normative data for non-psychiatric adult
populations were obtained for the depression instrument
used in that study (Brief Symptom Inventory - Depression
and Anxiety subscale) in the absence of baseline data [20].
In cases where approximations were provided, sensitivity
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analyses were conducted to determine their influence on
overall effect.
Where more than one instrument was used to mea-
sure mood state, the instrument most comparable with
those used in other included trials was selected. Simi-
larly, where more than one medication arm was
included in a trial, the statin agent deemed by the
author group to be most comparable with the others
included in the review was selected for inclusion in the
primary meta-analysis. We re-ran our analysis, imputing
data from the second statin arm in each of the multi-
arm studies, and it had no influence on results (data not
shown). To address heterogeneity among characteristics
of study samples (hypercholesterolemia, no hypercholes-
terolemia), sensitivity analyses were conducted.
Statistical analysis
The primary meta-analysis measured the effects of statin
use on psychological wellbeing (depression and mood) of
individuals with or without hypercholesterolemia com-
pared with a placebo, with follow-up periods ranging
from 4 weeks to 4 years. Meta-analyses were performed
using SMD for continuous outcome measures (based on
post-post means), with 95% CIs, using Review-Manager 5
software (RevMan Computer Program. Version 5.1.
Copenhagen: The Nordic Cochrane Centre. The
Cochrane Collaboration, 2011). We applied Hedges’
adjusted g to adjust for small sample bias. We explored
heterogeneity by calculating the I2 statistic and where
high I2 values were observed, sensitivity analyses was
conducted to exclude studies with potential bias or char-
acteristics that were not comparable. A priori subgroup
analysis estimated the effects of statins on psychological
outcomes by length of treatment period, type of statin
medication, and psychological outcome (for the purpose
of this paper and these analyses, the authors made a dis-
tinction between mood and depression in the latter suba-
nalysis for comparability purposes).
Results
The literature search was performed from February to
March 2012. Using the search terms ‘statins’ (simvastatin,
atorvastatin, fluvastatin, lovastatin, mevastatin, pitavasta-
tin, pravastatin, rosuvastatin, cerivastatin) ‘mood’ ‘dis-
tress’ ‘depress$’ ‘trial’ in bibliographic databases (OVID,
Cinahl, Scopus, Medline) and search engines revealed
1383 articles. After reviewing abstracts for relevance,
1370 did not meet inclusion criteria. Reasons for exclu-
sion are displayed in Figure 1, according to Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines [21]. Where uncertainty occurred,
authors reached consensus by consulting with the third
author. Examination of reference lists revealed one
potentially relevant article, which was ultimately excluded
because treatment and control groups remained deidenti-
fied due to the ongoing status of the trial at the time of
publication [22]. After completing this process, 13 arti-
cles remained. Further examination revealed that two
studies did not report depression, anxiety, mood, or dis-
tress outcomes; one was the same study identified
through previous search strategies; one evaluated a non-
pharmaceutical, dietary lipid lowering intervention; one
was a study without control condition; and one was the
aforementioned paper in which treatment and placebo
groups remained deidentified. Thus, these six articles
were excluded. After completing this process, seven arti-
cles remained for inclusion.
Study characteristics
Key characteristics are displayed in Table 1. The trials
included in the review were published from 1994 to
2006. Studies were conducted in the UK (n = 3) [23-25],
Scandinavia (n = 1) [19], Australia/New Zealand (n = 1)
[26], and the US (n = 2) [27,28]. All studies defined par-
ticipants in their samples as those with hypercholestero-
lemia or elevated serum cholesterol levels with the
exception of two, which comprised those with past cor-
onary disease (n = 1) [26], or medically healthy indivi-
duals (n = 1) [24].
Psychological wellbeing
Five studies reported depression outcomes at follow-up
using Hamilton Depression Rating Scale (clinician admi-
nistered) [28], Brief Symptom Inventory (self-report)
[19], Hospital Anxiety and Depression Scale (HADS)
(self-report) [24], General Health Questionnaire -
Depression and Anxiety (self-report) [26] and Center for
Epidemiology Studies Depression Scale (self-report) [27].
The remaining studies reported mood outcomes using
versions of the Profiles of Mood States [23,25]. Four stu-
dies measured anxiety using the General Health Ques-
tionnaire [26], HADS [24], Brief Symptom Inventory
[19], and the Profiles of Mood States [23].
Intervention
Details of treatment length and dosage are presented in
Table 1. Lovastatin (n = 2) [25,28], simvastatin (n = 4)
[19,23,24,27] and pravastatin (n = 3) [24-26] were the
statin agents evaluated in the seven studies. Two studies
included a three-arm design evaluating two statin arms
and one placebo arm [24,25]. The remaining five studies
comprised a two-arm design (statin versus placebo).
Upon consultation with the author group, the type of
statin chosen for inclusion in the main effects model for
these two studies were those most commonly evaluated
in the other studies.
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Trial quality results
We reviewed included studies using a set of quality cri-
teria developed by the Cochrane Centre. Based on this,
we concluded that the included studies were of sound
methodological quality. Where participant drop out
occurred, all studies reported a greater than approxi-
mately 80% retention rate. All studies used intention to
treat analysis. Details of how investigators and partici-
pants were blinded to treatment condition and the pro-
cess of randomization were unclear in most studies. The
key elements of trial quality for each study are presented
in Table 2.
Effect of statins on psychological wellbeing
The 7 RCTs included in the analysis represented 2,105
participants (1,133 treatment group versus 972 placebo
group). A test for overall effect demonstrated no signifi-
cant differences in psychological outcomes between par-
ticipants receiving statins (simvastatin, lovastatin,
provastatin) or a placebo (SMD = -0.08, 95% CI -0.29 to
0.12; P = 0.42) (Figure 1). Given the high heterogeneity
observed across studies (I2 = 71%), sensitivity analyses
were conducted to separately analyze depression (n = 5)
and mood (n = 2) outcomes. This analysis yielded low
heterogeneity (I2 = 0%) and revealed that statins were
associated with significant improvements in mood scores
(SMD = -0.43, 95% CI -0.61 to -0.24) (Figure 2), as mea-
sured by the Profile of Mood States.
When we compared long-term (3 to 4 years), intermedi-
ate (3 to 6 months) and short-term (4 weeks) effects of
statin use, no statistically significant differences were
observed between groups. When results were explored
separately for lovastatin, simvastatin and provastatin, sim-
vastatin was the only agent associated with psychological
improvements (SMD = -0.11, 95% CI -0.41 to 0.19),
although these effects were not significant.
Further sensitivity analyses were conducted to
exclude studies comprising participants with a CVD
history [26] or ‘healthy’ volunteers [24]; this had no
impact on results. In a separate analysis, we also
excluded studies from which we applied approxima-
tions [19,23,24]. The effect of statins on psychological
outcomes remained non-significant (SMD = -0.02, 95%
CI -0.25 to 0.20).
To explore the effects of statins on anxiety, we
included available data from studies that measured anxi-
ety, as distinct from depression (n = 3: one presented
data in graphical form [26], therefore were not included
in our analysis). This subanalysis compared anxiety data
of 419 treatment participants versus 222 control
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Figure 1 Study extraction and selection process.
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Table 1 Key characteristics of included studies.
Lead
author,
year,
reference
Study design Agent/dosage Sample Measure Presentation of
results
Key finding
Muldoon
2000 [28]
Double-blind,
randomized,
placebo-
controlled trial
Lovastatin (20 mg)/placebo 209 generally healthy adults with LDL cholesterol
level of 160 mg/dl or higher were randomized
(complete data: drug, n = 98; placebo, n = 96)
Hamilton
Depression Rating
Scale; NEO-
Depression
Means and SDs 24-week treatment of
hypercholesterolemia with lovastatin
did not cause psychological distress
Wardle
1996 [23]
Randomized,
placebo-
controlled trial
Simvastatin 20 mg or 40 mg
daily/placebo
621 individuals greater higher than average risk of
CHD based on medical history (total cholesterol of
≥3.5 mmol/l) were randomized (complete data: drug,
n = 334; placebo, n = 157)
Shortened profile
of Mood States
Questionnaire
Medians and
IQRs
152 weeks of cholesterol-lowering
treatment did not cause mood
disturbance
Hyyppa
2003c
Two separate
randomizations,
Double-blind,
crossover design
Simvastatin 20 mg/day plus
dietary intervention/placebo
120 hypercholesterolemic but otherwise healthy
middle-aged men (complete data: drug, n = 60;
placebo, n = 60)
Brief Symptom
Inventory
Mean difference
in change
scores between
groups, SEM
12 weeks of simvastatin resulted in a
statistically significant increase in
depression
Harrison
1994 [24]
Randomized,
crossover design
Sequential placebo,
pravastatin 40 mg day/
simvastatin 40 mg day, in
separate 4-week treatment
phases
25 healthy volunteers (17 male, 8 female), average
age 23.8 years. Drug, n = 25/n = 25; placebo, n = 25.
HADS score for pravastatin was 1.5 (0.6 to 2.4).
HADS, BDI
(baseline only)
Means and CIs No association between simvastatin
and depression or anxiety at 4 weeks
Gengo
1995 [25]
Randomized,
cross over design
Placebo, lovastatin (40 mg),
and pravastatin (40 mg) for 4
weeks
36 patients between the ages of 40 and 60 years
with moderate hypercholesterolemia. Drug, n = 24/n
= 24; placebo, n = 24. Mood scores for pravastatin 4.8
(6.5).
Profile of Mood
States (fatigue/
inertia)
Means and SDs After 4 weeks, no statistically
significant differences between
lovastatin in changes from baseline
were observed on any parameter
Stewart
2000 [26]
Randomized,
double-blind,
placebo-
controlled trial
Pravastatin sodium (40 mg/
day) for 4 years
1130 with stable CAD. Drug, n = 559; placebo, n =
571.
General Health
Questionnaire
(depression and
anxiety domains)
Means and SDs After 4 years no significant increases
in self-reported depression, anxiety
Morales
2006 [27]
Randomized,
placebo-
controlled trial
Simvastatin up to 20 mg/day
or placebo for 15 weeks
80 older volunteers, average age 70 years, with high
normal/mildly elevated serum cholesterol (placebo, n
= 39; drug completers, n = 33)
Center for
Epidemiology
Studies Depression
Scale
Mean and SDs After 3 months, drug group reported
decrease in positive affect
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Table 2 Methodological quality of studies.
Author,
year,
reference
Agent and dosage Randomization and concealment Quality of analysis
Muldoon
2000 [28]
Lovastatin (20 mg)/placebo Trained data collectors were blinded to subjects’
treatment assignment. Method of randomization
unclear.
All analyses were conducted on an intention-to-
treat basis. 7% attrition rate. Difference in
education levels of completers versus drop outs,
but no other key characteristics. In several
instances, test scores were transformed to ensure
normality.
Wardle
1996 [23]
Simvastatin 20 mg or 40 mg
daily/placebo
Follow-up data collection was blinded. Method
of randomization unclear.
Intention to treat used. Medians and IQRs used.
Study had good statistical power to detect a
shift in the distribution of the total score of the
profile of mood questionnaire.
Hyyppa
2003 [23]
Simvastatin 20 mg/day plus
dietary intervention/placebo
All measurements and analyses were performed
blinded to the treatment allocation of the
participant. Method of randomization unclear.
Intention to treat not mentioned, however
attrition rate was 0%. Where necessary, log or
square root transformations were applied.
Harrison
1994 [24]
Sequential placebo, pravastatin 40
mg day/simvastatin 40 mg day, in
separate 4-week treatment phases
Volunteers were blind to which medication they
were receiving. Investigators were blind to drugs
administered during the treatment phases but
not the placebo washout phases. Method of
randomization unclear.
Intention to treat not mentioned, however
attrition rate was 0%
Gengo
1995 [25]
Placebo, lovastatin (40 mg), and
pravastatin (40 mg) for 4 weeks
Method of randomization or concealment
unclear
Intention to treat not mentioned, however
attrition rate was 0%
Stewart
2000 [26]
Pravastatin sodium (40 mg/day)
for 4 years
Process of randomization or concealment was
unclear
Intention to treat used, with the exception of the
relation between a change in cholesterol level
and psychological outcome. Baseline response
rate was 93%. Response rate at follow-up
assessments: the response rate was 90% at 6
months, 90% at 1 year, 88% at 2 years, and 77%
at 4 years.
Morales
2006 [27]
Simvastatin up to 20 mg/day or
placebo for 15 weeks
Blinding: To maintain the double-blind, all
medication was prepared in opaque, identical-
appearing red-and-blue gelatin capsules, which
were sealed in blister cards with each individual
dose identified on the packaging by the day and
the time it was to be taken. Process of
randomization unclear.
Intention to treat analysis used. Mixed effects
models used. Where data were not normally
distributed, data were transformed/used as
binary outcomes. Results were reported in terms
of the change in positive affect per day. Given a
high degree of colinearity between group
assignment and final cholesterol status, these
models did not control for treatment group in
the analysis of the effect of cholesterol status on
outcome. In all, 79% of subjects assigned to
placebo and 80% receiving simvastatin
completed the study.
 
Figure 2 Overall effect of statin treatment on psychological outcomes of individuals with and without hypercholesterolemia.
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participants, revealing no significant between-group dif-
ferences (SMD = -0.01, 95% CI -0.17 to 0.16).
Discussion
The aim of the study was to determine the impact of
statins on psychological wellbeing by conducting the
first meta-analysis of its kind. Overall, pooled effects of
seven RCTs demonstrated no adverse or beneficial
effects of statins on psychological outcomes. These find-
ings do not provide support for observational studies
that have demonstrated either adverse [5] or protective
effects of statins on psychological outcomes in healthy
[12] and cardiac populations [10,11]. However, when a
sensitivity analysis was conducted to include only those
studies evaluating mood, statistically significant effects
in favor of treatment were observed. Using Cohen’s
interpretation of effects, this effect size is considered of
medium magnitude [29]. While these findings should be
considered with caution due to the limited number of
studies included in this subanalysis, they provide some
evidence to refute previous suggestions that lipid lower-
ing medications may lead to adverse psychological out-
comes. In fact, these data highlight a potential for
statins to produce mood-related benefits. This finding is
consistent with those RCTs conducted in hypercholes-
terolemia populations that have observed positive effects
on mental health-related quality of life (QoL) [22].
There are several mechanisms by which these effects
could be explained. There is now a body of evidence for
an etiological role of inflammation and oxidative stress
in the pathophysiology of depression [30,31]. As statins
have anti-inflammatory and antioxidant properties, it
has been suggested that these properties may target the
inflammatory and oxidative pathways associated with
the pathophysiology of the disorder [32]. Alternatively,
because individuals using statins are known to exhibit a
decreased risk of cardiovascular events, it is possible
that statin-induced mood improvements may be a func-
tion of improved QoL or a greater degree of health con-
sciousness for individuals receiving long-term treatment
[33].
Large-scale clinical trials with long-term outcomes are
required to evaluate the effect of statins on psychologi-
cal wellbeing of individuals with depression. When con-
ducting our review, we were unable to identify any
studies of this type. Because there is some support for
the role of statins as a protective mechanism against the
development of depression [10], a trial of this nature
may offer a novel approach to the treatment and pri-
mary prevention of depression through exploring the
role of inflammatory processes as a potential therapeutic
target. Our findings provide some support for a favor-
able risk-benefit profile of statins in terms of mood out-
comes for those with and without hypercholesterolemia.
Statins were not linked to mood-related disturbances,
but rather benefits, which may be due to their substan-
tial anti-inflammatory and antioxidative properties. If
statin-induced improvements in mood are observed in
those with existing depression, the benefits of statins
may go beyond that of reducing CVD-related outcomes
to depression prevention or therapy. Not only are statins
affordable and accessible, but additional benefits exist
for those with comorbid conditions that are dispropor-
tionally more common in individuals with depression
(for example, CVD) [34], because of their impact on
shared pathophysiological processes (for example,
inflammation) [31].
This meta-analysis has several limitations. Due to the
fundamental nature of meta-analyses, where data from
independent studies are synthesized, it is acknowledged
that unexplained variances may exist, demonstrated by
the high degree of heterogeneity observed between stu-
dies. For example, it is acknowledged that psychological
wellbeing was assessed using different instruments that
may measure different constructs. Further, only one
study reported using a clinician-administered instru-
ment; the majority of studies used self-report inventories
to assess depression and/or anxiety. Therefore, it is
recommended that future research pay greater attention
to determining the efficacy of statins related to psycho-
logical outcomes, employing diagnostic psychiatric inter-
views to measure these constructs. Although time
consuming, this is an accurate method for classifying
mood disorders.
Additionally, it is acknowledged that the limited num-
ber of studies included in this review may have intro-
duced bias. For example, it is likely that the file drawer
effect influenced the findings of this study. This phe-
nomenon sees published studies reporting inflated effect
sizes and those yielding negative results remaining
unpublished. This is of particular relevance to meta-ana-
lyses evaluating the effects of pharmacological interven-
tions. While funnel plots could provide an indication of
publication bias, they were not displayed in this paper,
as it has been reported that more than ten estimates are
required to reliably judge funnel plots [35]. Small sam-
ple size further precluded extensive subanalyses of the
data, due to limited power (for example, to determine
specific effects between those with hypercholesterolemia
versus established coronary disease versus healthy parti-
cipants). Future research comprising a greater number
of studies is required to confirm our findings.
Conclusions
Our findings refute previous evidence of the negative
effects of statins on psychological outcomes, and provide
some support for mood-related benefits. Further
research comprising a greater number of studies is
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required to confirm the effects of this agent on psycho-
logical outcomes. RCTs could further examine the
effects of statins in depressed populations.
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